Search Results
Your search for ,are matches 22257 pages
Showing 201 - 250Phase III Trial Supports Intensified Total Neoadjuvant Therapy in High-Risk Rectal Cancer
In a multicenter Chinese randomized phase III trial published in the Journal of Clinical Oncology, Wang et al found that an intensified total neoadjuvant therapy approach integrating long-course radiotherapy with uninterrupted capecitabine and oxaliplatin chemotherapy improved disease-free survival ...
Technology-Enabled Intervention for HCT Recipients, Primary Care Doctors May Improve Skin Cancer Screening
Recipients of hematopoietic cell transplant (HCT) are at increased risk of skin cancer and screening for early detection is encouraged. New research published by Armenian et al in JNCCN—Journal of the National Comprehensive Cancer Network shows how a technology enabled, remotely delivered,...
Teclistamab Improves Progression-Free and Overall Survival in Previously Treated Multiple Myeloma
In the phase III MajesTEC-9 trial, monotherapy with the bispecific antibody teclistamab kept disease under control substantially longer and improved overall survival compared with investigator’s choice of pomalidomide/bortezomib/dexamethasone (PVd) or carfilzomib/dexamethasone (Kd) in patients with ...
Durvalumab Plus BCG Improves Outcomes in High-Risk Non–Muscle-Invasive Bladder Cancer
Adding the PD-L1 inhibitor durvalumab to bacillus Calmette-Guérin (BCG) induction and maintenance therapy delayed high-risk events and improved cystectomy-free survival in patients with BCG-naive, high-risk non–muscle-invasive bladder cancer (NMIBC), according to expanded analyses from the phase...
AMH Levels May Predict Adjuvant Chemotherapy Benefit in Premenopausal Women With Breast Cancer
In premenopausal women under the age of 55 years with hormone receptor–positive, HER2-negative, node-positive breast cancer, investigators reported that those with low baseline levels of anti-Mullerian hormone (AMH) did not benefit from adjuvant chemotherapy and endocrine therapy. The findings from ...
WHO Calls for Action in New Status Report on Cancer
Cancer is the second leading cause of death globally, after cardiovascular disease, and claims more than 26,000 lives daily, according to a report from the WHO Global Status Report on Cancer 2026, developed jointly with the International Agency for Research on Cancer (IARC). The report was issued...
FDA Approves Oncolytic Viral Therapy With Immunotherapy for Advanced Melanoma
On August 6, the U.S. Food and Drug Administration (FDA) granted accelerated approval to vusolimogene oderparepvec-wtpg (Tudriqev), a genetically modified oncolytic viral therapy, in combination with nivolumab for the treatment of adult patients with unresectable advanced cutaneous melanoma who...
New Data on 14- vs 28-Day Venetoclax/Azacitidine in AML
New results from Blood Cancer United’s Beat AML Master Clinical Trial published by Borate et al in the journal Blood provide new information about whether older patients with newly diagnosed acute myeloid leukemia (AML) can receive a shorter schedule of venetoclax when it is given in combination...
HER2-Targeted Regimen Yields High Pathologic Complete Response Rate in Locally Advanced Breast Cancer
A human epidermal growth factor receptor 2 (HER2)–targeted regimen achieved high pathologic complete response rates before surgery in patients with locally advanced HER2-positive breast cancer, according to results from the single-arm phase II neoPICD trial. The findings were highlighted during a...
Combination Regimen Prolongs PFS in dMMR/MSI-H Metastatic Colorectal Cancer
The combination of mFOLFOX6, bevacizumab, and atezolizumab prolonged progression-free survival over atezolizumab monotherapy in the first-line setting for patients with mismatch repair–deficient/microsatellite instability–high (dMMR/MSI-H) metastatic colorectal cancer, according to findings from...
When Diagnosis Waits: Lung Cancer, PET Access, and Global Oncology
A few weeks ago, a friend in the United States reached out to me about her sister in Rwanda, a woman in her 40s with no history of smoking. Her chest pain had progressively worsened to the point of becoming unbearable. CT imaging revealed a concerning lung mass highly suggestive of malignancy. One...
AI-Based cfDNA Fragmentome Classifier May Improve Detection of HCC
Researchers have developed and validated an artificial intelligence (AI)-powered liquid biopsy that accurately identified hepatocellular carcinoma (HCC) based on cell-free DNA (cfDNA) fragments in individuals from two distinct populations, according to research findings published in Cell Press...
U.S. News & World Report Announces 2026–2027 Best Cancer Hospitals
U.S. News & World Report today released the 2026–2027 edition of Best Hospitals. Now in its 37th year, the annual study helps patients and their families make informed, data-driven health-care decisions in consultation with their medical providers and care teams. The top 10 hospitals for the...
Next-Generation Sequencing Uptake Remains Low Among Medicare Beneficiaries, Study Finds
While there has been a recent increase among Medicare recipients in uptake of genomic testing that helps match patients with cancer to the most effective treatment for their tumor, many Medicare beneficiaries with cancer are still not receiving next-generation sequencing (NGS), according to a new...
Quantum Machine Learning Framework Improves Prediction of Antigen Presentation and Immunotherapy Response
Researchers from Cleveland Clinic and IBM have jointly developed a framework for using quantum computing to make predictions of antigen presentation and immunotherapy response, according to the study results published in Science Advances. The framework, called Quantum Convolutional HLA Immunogenic ...
Safety and Efficacy of IL-10–Expressing CAR T-Cell Therapy in Relapsed or Refractory DLBCL
In a nonrandomized phase I trial published in JAMA Oncology, ultra low–dose interleukin (IL)-10–expressing chimeric antigen receptor (CAR) T-cell therapy (META 10-19) appeared to be safe and active in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). Hu et al noted that...
FDA Approves Radionuclide Therapy Plus ARPI for mAPMN/S Prostate Cancer
On July 31, the U.S. Food and Drug Administration (FDA) approved lutetium-177–labeled PSMA-617 (vipivotide tetraxetan, also known as LuPSMA-617; Pluvicto), a targeted radionuclide therapy, in combination with androgen receptor pathway inhibitor (ARPI) therapy for adults with prostate-specific...
ACS Study Quantifies Financial Burden of Cancer in Older Patients
Costs from treatments and medical services for older adults (66 years and older) with cancer vary significantly by a number of factors, including cancer type and stage, but rising costs tended to impact patients most in the end-of-life stage of care, according to findings from a study published in...
Pirtobrutinib Triplet Improves Progression-Free Survival in Previously Treated CLL
In the randomized phase III BRUIN CLL-322 trial, adding fixed-duration pirtobrutinib, a non-covalent Bruton tyrosine kinase (BTK) inhibitor, to venetoclax-rituximab significantly improved progression-free survival in patients with previously treated chronic lymphocytic leukemia or small lymphocytic ...
Rectal Cancer: AI Identifies Patients Most Likely to Benefit From Irinotecan-Intensified Neoadjuvant Chemoradiotherapy
Higher tumor cell density in patients with locally advanced rectal cancer receiving irinotecan-intensified neoadjuvant chemoradiotherapy was associated with improved survival outcomes compared with those treated with standard chemoradiotherapy, according to findings from a post-hoc analysis of the...
Case Series Supports High-Dose Oral Vitamin D for Cancer Therapy–Related Skin Toxicities
A retrospective multicenter case series published by Patil et al in JAMA Dermatology found high-dose oral vitamin D therapy to be associated with rapid symptomatic and objective improvement in chemotherapy- and radiation therapy–induced skin toxicities, without treatment-related adverse events....
Germline Genetic Variants Associated With CAR T-Cell Therapy Safety and Efficacy in Hematologic Malignancies
Germline genetics impact the safety and efficacy of engineered chimeric antigen receptor (CAR) T-cell therapies in patients with hematologic malignancies, according to study findings published in Science Immunology. “These findings have important implications for understanding how CAR T cells...
FDA Approves SimpleScreen CRC Blood-Based Screening Test for Colorectal Cancer
The U.S. Food and Drug Administration (FDA) has approved SimpleScreen CRC, a new blood-based screening option for colorectal cancer in adults aged 45 years and older who are at average risk for the disease. The test is produced by Freenome; Abbott will exclusively commercialize the test in the...
Global Breast Cancer Survival Estimates: WHO Analysis
For the first time ever, the World Health Organization (WHO) has published global 5-year breast cancer survival estimates for women diagnosed with breast cancer between 2017 and 2021 for all its 194 Member States. Published by Girardi et al in Nature Medicine, these estimates provide a baseline for ...
Concurrent Palliative Care Remains Underused Among Young Adults With Advanced Cancer
Concurrent uptake of palliative care has remained low in young adults with advanced cancers, according to the results of a retrospective cohort study published in JAMA Network Open. “Palliative care can help address symptoms, support decision-making, and improve quality of life during treatment,...
FDA Releases Final Guidances to Expand Participation in Cancer Clinical Trials
The FDA’s Oncology Center of Excellence announced three final guidance documents intended to broaden eligibility criteria for participation in clinical trials of oncology drugs. Fewer than 5% of patients with cancer currently receiving treatment are enrolled in clinical trials—even though more...
ELEVATE Trial Shows Disease-Free Survival Benefit With Adjuvant Ensartinib in ALK-Positive NSCLC
In an interim analysis of the phase III ELEVATE trial reported in The New England Journal of Medicine, Yue et al found that patients with completely resected ALK-positive non–small cell lung cancer (NSCLC) who received adjuvant ensartinib experienced significantly longer disease-free survival than...
Avatrombopag Manages Persistent Chemotherapy-Induced Thrombocytopenia in GI Cancer
Avatrombopag successfully managed persistent chemotherapy-induced thrombocytopenia in patients with gastrointestinal cancer, according to findings from the randomized phase II ACT-GI trial published in the Journal of Clinical Oncology. “Chemotherapy remains a cornerstone of therapy for...
Relapsed or Refractory Multiple Myeloma: Early-Phase Trial Investigates Novel Bispecific Antibody
In a phase I clinical trial, treatment with the investigational FcRH5×CD3 bispecific antibody cevostamab reduced cancer in more than 40% of patients with multiple myeloma—many of whom had already been through multiple other cancer treatments—and produced a median duration of response of 11.2 months ...
Discovery Is an Act of Hope: Remembering Dr. Maura Gillison’s Pursuit of Truth
Maura Gillison did not chase awards. She chased answers, and especially clinically impactful answers. That distinction between the pursuit of recognition and the pursuit of truth defined everything about her as a scientist, a clinician, and a person. She was direct with compassion, generous to the ...
The Fear of Having Cancer Never Goes Away
There is a strong history of breast cancer in my family, and the fact that I have dense breasts adding to my risk of developing the disease, kept me vigilant about getting a yearly mammogram screening since I turned 32. The test never showed any suspicious lesions over the last nearly 2 decades,...
ASCO Publishes First Guideline on ctDNA Testing in Solid Tumors and Lymphoma
A panel of ASCO experts voted to approve ASCO’s first guideline on ctDNA testing in patients with solid tumors or lymphoma on November 18, 2025.1 The guideline addresses four overarching clinical questions: when ctDNA testing should (or should not) be used to (1) support cancer diagnosis; (2)...
Access Denied: Insurance Barriers to Biomarker Testing in Lung Cancer
In the past few decades, the rapidly growing field of precision medicine has improved the survival of patients with lung cancer. Yet the benefits of these therapies do not reach all patients. Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, yet most patients are diagnosed ...
Paraneoplastic Neurological Syndromes Associated With Improved Survival in SCLC
Patients with small cell lung cancer (SCLC) and type 1 antineuronal nuclear or “Hu” antibody (ANNA1/Hu-IgG)–related paraneoplastic neurological syndromes (PNS) may experience longer survival, according to the results of a study published in Journal of Neurology. Additionally, in those with...
Neoadjuvant Inetetamab Plus Pyrotinib Evaluated in HER2-Positive Locally Advanced Breast Cancer in China
Neoadjuvant treatment with the HER2-targeted monoclonal antibody inetetamab in combination with the irreversible pan-HER tyrosine kinase inhibitor pyrotinib (inhibits HER1, HER2, HER4) and chemotherapy produced high pathologic response rates in patients in China with HER2-positive locally advanced...
FDA Approves Zidesamtinib for Second-Line Treatment of ROS1-Positive NSCLC
On July 22, the U.S. Food and Drug Administration (FDA) approved zidesamtinib (Jideytro), a ROS1 selective inhibitor, for the treatment of adult patients with locally advanced or metastatic ROS1-positive non–small cell lung cancer (NSCLC) who received a prior ROS1 kinase inhibitor. The approval...
POLARGO Trial Shows Survival Benefit With Polatuzumab Vedotin–Based Regimen in Relapsed or Refractory DLBCL
According to the results of the phase III POLARGO trial reported by Matasar et al in the Journal of Clinical Oncology, adding polatuzumab vedotin-piiq to rituximab, gemcitabine, and oxaliplatin (Pola-R-GemOx) significantly improved overall survival compared with standard rituximab, gemcitabine, and ...
AI-Derived Bone Marrow Architecture Score Improves Disease Assessment in Myelodysplastic Neoplasms
Mapping bone marrow architecture provided a more accurate view of disease state in myelodysplastic neoplasms (MDS) than molecular or blast-based assessments, according to research findings published in Leukemia. The researchers created an AI-based score to assess disease status and changes over...
ASCO 2026: Multiple Myeloma Studies Highlight Advances Across the Field
The plasma cell dyscrasia oral abstract session at the 2026 ASCO Annual Meeting featured several pivotal trials that advanced the field, including those highlighted here. Coverage of new treatments for amyloidosis will appear in a separate article. Mezigdomide-Based Regimen Improves...
Can Consolidative Thoracic Radiotherapy Improve Outcomes During Immunotherapy Maintenance in Extensive-Stage SCLC?
Consolidative thoracic radiotherapy added to standard maintenance immunotherapy increased toxicity without improving survival in first-line extensive-stage small cell lung cancer (SCLC), according to findings from the multicenter phase II TREASURE (AIO-TRK-0320) trial published in JAMA Oncology....
Early Research Examines Daraxonrasib in NRAS-Mutant Melanoma
A research team has reported that a groundbreaking pathway-targeted therapy may be an effective treatment for certain melanoma patients and fill an unmet clinical need for patients with advanced disease. Martin McMahon, PhD, Senior Director of Preclinical Translation at Huntsman Cancer Institute...
Emergency Department Cancer Diagnosis Associated With Higher Mortality Across 16 Cancer Types
Diagnosis of a cancer upon emergency department presentation was associated with an elevated mortality rate, which was consistent across 16 analyzed cancer types, according to new research findings published in the Journal of the National Cancer Institute. “These gaps held up even after we...
Integrating Environmental Health Into Pediatric Cancer Care May Improve Outcomes
A review of the scientific literature on the impact of environmental factors on the health of pediatric cancer survivors by Omar Shakeel, MD, Assistant Professor in the Department of Pediatrics, Division of Hematology-Oncology at Baylor College of Medicine and Head of the Long-Term Survivor Clinic ...
Early Trial Supports KRAS Vaccine Strategy for Pancreatic Cancer Interception
A vaccine targeting common KRAS mutations was safe and stimulated KRAS-specific T-cell responses in 90% of study participants who were at high risk of developing pancreatic ductal adenocarcinoma (PDAC), according to phase I clinical trial results published by Haidar et al in Cancer Discovery....
National Survey Links Civic Engagement to Higher Breast Cancer Screening Rates
Findings from a National Health Interview Survey revealed that civically engaged adults were more likely to stay up to date with their breast cancer screenings. The research findings were published in the American Cancer Society's Cancer journal. “The connection isn’t surprising, as being...
EMERALD-3 Shows Benefit With STRIDE Plus TACE in Hepatocellular Carcinoma
Results of the phase III EMERALD-3 trial showed that combining transarterial chemoembolization (TACE) with the immunotherapy-based STRIDE regimen, (single tremelimumab[an anti-cytotoxic T lymphocyte–associated antigen 4] plus regular interval durvalumab [anti–PD-L1]) with or without lenvatinib...
Study Finds Rising Breast Cancer Incidence Across Asian American, Native Hawaiian, and Pacific Islander Groups
Based on the results of a population-based, descriptive, cross-sectional study published in JAMA Network Open by Gomez et al, invasive breast cancer incidence rates accelerated among Asian American, Native Hawaiian, and Pacific Islander women over 2 decades. “The rapid recent increases in breast...
ctDNA Status May Predict Benefit From Adjuvant Chemotherapy After Resection of Colorectal Liver Metastases
Circulating tumor DNA (ctDNA) for molecular residual disease tracking could help identify patients with colorectal cancer and liver metastases who are most likely to benefit from adjuvant chemotherapy after surgery, according to findings from an overall survival analysis of the phase II GALAXY...
Tumor Microenvironment Ecotypes May Explain Differences in Multiple Myeloma Outcomes
Researchers have created a comprehensive single-cell map of the tumor immune microenvironment in multiple myeloma and its precursor conditions. The newly published findings provide insights that may explain why patients with similar diagnoses often have differences in disease progression, treatment ...
How Do Surgical Ovarian Cancer Prevention Strategies Compare for Sexual Function?
In a prospective, multicenter, nonrandomized patient-preference trial published in JAMA Network Open, interval salpingectomy with delayed oophorectomy (ISDO) was associated with less impairment in sexual function than risk-reducing salpingo-oophorectomy (RRSO) among premenopausal women at high risk ...
